USA-based EyeGate Pharmaceuticals, a specialist developer of therapeutics for eye disorders, says it has earned an additional $15.0 million though a series C venture financing round. The firm added that Medicis Capital had joined previous investors Ventech, Innoven Partenaires and the Nexus Group in the round, which in total raised $31.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze